New method for early detection of liver cancer
Peptide multimer for early detection of hepatocellular carcinoma
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10979395
This study is working on a new way to spot liver cancer early by using tiny protein pieces that can help doctors see the difference between harmful tumors and non-cancerous growths, making it easier to diagnose and treat patients with liver cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10979395 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a peptide multimer that can serve as a new imaging biomarker for the early detection of hepatocellular carcinoma (HCC), a rapidly increasing type of liver cancer. By utilizing single-cell RNA sequencing and trajectory analysis, the study aims to identify specific molecular targets within HCC cells that can distinguish malignant tumors from benign lesions. The smaller size of peptides compared to traditional antibodies allows for better penetration into tumors, potentially improving diagnostic accuracy and treatment strategies for patients. This innovative approach seeks to enhance the management of HCC by providing more reliable early detection methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for hepatocellular carcinoma, such as those with chronic liver disease or cirrhosis.
Not a fit: Patients with advanced liver cancer or those who do not have liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of liver cancer, improving treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using peptide-based biomarkers for cancer detection, indicating potential success for this novel approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, THOMAS D — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: WANG, THOMAS D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.